Home / Market News / $MEDS

$MEDS news and market catalysts

The 15 most recent market catalysts affecting $MEDS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 4 high impact 8 bullish 2 bearish Pharmaceuticals Retail
Nov 6, 2026 Corporate Catalyst Neutral Impact 55
Meds Apotek AB Releases Q3 2026 Interim Report
Meds Apotek AB's Q3 2026 interim report provides a mixed bag of news. The successful operationalization of the Eskilstuna logistics center is a positive long-term development, sugg…
Nov 4, 2026 Corporate Catalyst Neutral Impact 75
DataMeds AI Terminates Letter of Intent Involving Scilex Holding Company
DataMeds AI (MEDS) announced the termination of a letter of intent to acquire intellectual property from Scilex Holding Company (SCLX), citing 'market conditions.' This is a signif…
Nov 3, 2026 Corporate Catalyst Bullish Impact 65
DataMEDS AI Secures Commercial Supply Agreement for Six Compounded Peptides
DataMEDS AI announced a commercial supply agreement for six compounded peptides, which represents a strategic expansion into a new product category. This is significant because it …
Oct 14, 2026 Corporate Catalyst Neutral Impact 65
DataMeds AI To Collaborate With REBOOT Health AI To Integrate Its GLP Management Platform Into Its Health Lives Here Mobile App Under License Agreement
DataMeds AI (MEDS) has secured an exclusive license from REBOOT Health AI to integrate a GLP Management Platform into its 'Health Lives Here' mobile app. This is a significant stra…
Oct 12, 2026 Corporate Catalyst Bullish Impact 75
DataMeds AI Stock Rises After Humana Adds Medicaid Coverage for ChemoFx Cancer Test
DataMeds AI's stock surged after Humana, a major insurer, expanded its Medicaid coverage to include the ChemoFx assay for gynecologic cancers. This development is crucial for DataM…
Oct 12, 2026 Corporate Catalyst Neutral Impact 65
Datameds AI Subsidiary Helomics Receives Medicaid Coverage Determination In Gynecologic Cancers For The ChemoFx Assay In Gynecologic Cancers
DataMeds AI's subsidiary Helomics announced that its ChemoFx Assay, a chemoresponse test for gynecologic cancers, has received Medicaid coverage from Humana. This is a positive dev…
Sep 28, 2026 Corporate Catalyst Neutral Impact 55
Reported Earlier: DataMeds AI, Tollo Health Roll Out Health Lives Here Mobile Application
DataMeds AI and Tollo Health have launched a new mobile application, 'Health Lives Here,' specifically designed to support users of GLP-1 receptor agonist medications. This represe…
Sep 28, 2026 Corporate Catalyst Bullish Impact 75
DataMeds AI Stock Surges on Mobile App Launch
DataMeds AI announced the launch of its 'Health Lives Here' mobile application, a significant corporate catalyst. This app expands the company's telehealth and AI diagnostic capabi…
Sep 18, 2026 Market Technicals Bullish Impact 55
12 Health Care Stocks Moving In Friday's After-Market Session
This filing, generated by an automated content engine, simply reports the after-market price changes for a selection of healthcare stocks. It does not provide the underlying reason…
Sep 17, 2026 Corporate Catalyst Bearish Impact 65
Nebius Group, DataMEDS AI, Boeing, Generac Holdings and Delixy Holdings: Why These 5 Stocks Are on Investors' Radars Today
The filing details several distinct corporate catalysts driving investor interest in these five stocks. Nebius Group (NBIS) is benefiting from a strategic partnership with Palantir…
Sep 16, 2026 Corporate Catalyst Bullish Impact 95
DataMEDS AI Stock Surges Wednesday: What's Driving the Action?
DataMEDS AI's acquisition of Helomics Corporation is a significant corporate catalyst. This move immediately thrusts DataMEDS into the lucrative $40 billion U.S. cancer diagnostic …
Sep 16, 2026 Corporate Catalyst Bullish Impact 95
Market-Moving News for September 16th
The filing highlights three distinct corporate catalysts. DataMEDS (MEDS) experienced a massive 181% surge due to its acquisition of Helomics AI Cancer Diagnostics Lab and Precisio…
Sep 16, 2026 Corporate Catalyst Bullish Impact 92
DataMEDS AI Stock Soars 65% Pre-market: Here's What You Need to Know
DataMEDS AI (MEDS) announced the completion of its acquisition of Helomics Corp., an AI-driven cancer diagnostics laboratory, from Axe Compute Inc. (AGPU) for $1.5 million. This is…
Aug 17, 2026 Corporate Catalyst Bearish Impact 95
DataMEDS AI Q2 EPS $(7.13) Down From $(5.40) YoY, Sales $1.780M Down From $7.791M YoY
DataMEDS AI reported a substantial increase in losses per share, from $(5.40) to $(7.13) year-over-year, alongside a dramatic 77.15% drop in sales from $7.791 million to $1.780 mil…
Jul 29, 2026 Corporate Catalyst Bullish Impact 65
DataMeds AI, Datavault AI Amend Definitive Agreement To Expand PharmacyChain Blockchain-Related Technology Licensing Relationship Beyond Pharmaceutical Distribution
DataMeds AI and Datavault AI have expanded their existing definitive agreement, allowing DataMeds AI to license Datavault AI's PharmacyChain blockchain technology for a much wider …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.